Strategies to decrease ongoing oxidant burden in chronic obstructive pulmonary disease

Expert Review of Clinical Pharmacology

Volumn 5, Issue 3, 2012, Pages 293-309

  Rahman, Irfan ^a   Kinnula, Vuokko L ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

antioxidants; COPD; glutathione; Nrf2; oxidants; redox; thiol; tobacco smoke

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; 2,2' DITHIODIPYRIDINE; 21 AMINOSTEROID; 3 CHLOROTYROSINE; ACETYLCYSTEINE; CARBOCISTEINE; CHALCONE; CIGARETTE SMOKE; DIETHYLSTILBESTROL; DISUFENTON SODIUM; EBSELEN; ERDOSTEINE; FUDOSTEINE; HYDROGEN PEROXIDE; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LACTOFERRIN; LIPOCALIN; LYSINE DERIVATIVE; MYELOPEROXIDASE; NITRIC OXIDE SYNTHASE; NORPHENAZONE; PEROXYNITRITE; SEMIQUINONE; SULFORAPHANE; SUPEROXIDE DISMUTASE; THIONEINE; THIOREDOXIN; TIRILAZAD; UNINDEXED DRUG; XANTHINE OXIDASE;

ASTHMA; BRONCHIECTASIS; CELL FUNCTION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COCHRANE LIBRARY; DISEASE COURSE; DNA MODIFICATION; ENZYME INDUCTION; EOSINOPHIL; EXPIRED AIR; HUMAN; IN VIVO STUDY; INFLAMMATORY CELL; LUNG BIOPSY; LUNG LAVAGE; NEUTROPHIL; NITROSATIVE STRESS; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROTEIN CARBONYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY CHAIN; RESPIRATORY TRACT INFLAMMATION; REVIEW; SMOKING; SPIN TRAPPING; SPIROMETRY; SPUTUM ANALYSIS; SYSTEMATIC REVIEW (TOPIC);

ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; FREE RADICALS; HUMANS; INHALATION; OXIDANTS; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKE; SMOKING;

EID: 84861421537     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.16     Document Type: Review

References (190)

1. Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370(9589), 741-750 (2007
2. Hu G, Zhou Y, Tian J et al. Risk of COPD from exposure to biomass smoke: a meta-analysis. Chest 138(1), 20-31 (2010
3. Pillai SG, Kong X, Edwards LD et al. Loci identified by genome-wide association studies influence different disease-related phenotypes in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 182(12), 1498-1505 (2010
4. Eisner MD, Anthonisen N, Coultas D et al. An official American thoracic society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 182(5), 693-718 (2010
5. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59(7), 574-580 (2004
6. Wouters EF, Reynaert NL, Dentener MA, Vernooy JH. Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: is there a connection? Proc. Am. Thorac. Soc. 6(8), 638-647 (2009
7. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur. Respir. J. 28(1), 219-242 (2006
8. Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 176(6), 532-555 (2007
9. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu. Rev. Pathol. 4, 435-459 (2009
10. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 378(9795), 1015-1026 (2011
11. Martinez FJ, Donohue JF, Rennard SI. The future of chronic obstructive pulmonary disease treatment-difficulties of and barriers to drug development. Lancet 378(9795), 1027-1037 (2011
12. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in nonsmokers. Lancet 374(9691), 733-743 (2009
13. Willemse BW, ten Hacken NH, Rutgers B, Lesman-Leegte IG, PostmaDS, Timens W. Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers. Eur. Respir. J. 26(5), 835-845 (2005
14. Gamble E, Grootendorst DC, Hattotuwa K et al. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. Eur. Respir. J. 30(3), 467-471 (2007
15. Louhelainen N, Rytila P, Haahtela T, Kinnula VL, Djukanovic R. Persistence of oxidant and protease burden in the airways after smoking cessation. BMC Pulm. Med. 9, 25 (2009
16. Louhelainen N, Stark H, Mazur W, Rytila P, Djukanovic R, Kinnula VL. Elevation of sputum matrix metalloproteinase-9 persists up to 6 months after smoking cessation: a research study. BMC Pulm. Med. 10, 13 (2010
17. Rahman I, Kinnula VL, Gorbunova V, Yao H. SIRT1 as a therapeutic target in inflammaging of the pulmonary disease. Prev. Med. doi:10.1016/j. ypmed.2011.11.014 (2011) (Epub ahead of print
18. Elkington PT, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 61(3), 259-266 (2006
19. MacNee W. Accelerated lung aging: a novel pathogenic mechanism of chronic obstructive pulmonary disease (COPD). Biochem. Soc. Trans. 37(Pt 4), 819-823 (2009
20. Yao H, Rahman I. Current concepts on oxidative/carbonyl stress, inflammation and epigenetics in pathogenesis of chronic obstructive pulmonary disease. Toxicol. Appl. Pharmacol. 254(2), 72-85 (2011
21. Koli K, Myllarniemi M, Keski-Oja J, Kinnula VL. Transforming growth factor-b activation in the lung: focus on fibrosis andreactive oxygen species. Antioxid. Redox. Signal 10(2), 333-342 (2008
22. Barnes PJ, Chowdhury B, Kharitonov SA et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 174(1), 6-14 (2006
23. Kharitonov S, Alving K, Barnes PJ. Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task Force. Eur. Respir. J. 10(7), 1683-1693 (1997
24. Rahman I, Biswas SK. Noninvasive biomarkers of oxidative stress: reproducibility and methodological issues. Redox. Rep. 9(3), 125-143 (2004
25. Louhelainen N, Myllarniemi M, Rahman I, Kinnula VL. Airway biomarkers of the oxidant burden in asthma and chronic obstructive pulmonary disease: current and future perspectives. Int. J. Chron. Obstruct. Pulmon. Dis. 3(4), 585-603 (2008
26. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 370(9589), 797-799 (2007
27. Church DF, Pryor WA. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ. Health Perspect. 64, 111-126 (1985
28. Pryor WA, Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann. NY Acad. Sci. 686, 12-27 (1993
29. Saetta M, Baraldo S, Zuin R. Neutrophil chemokines in severe exacerbations of chronic obstructive pulmonary disease: fatal chemoattraction? Am. J. Respir. Crit. Care Med. 168(8), 911-913 (2003
30. Kinnula VL, Crapo JD, Raivio KO. Generation and disposal of reactive oxygen metabolites in the lung. Lab. Invest. 73(1), 3-19 (1995
31. Byers DE, Holtzman MJ. Alternatively activated macrophages and airway disease. Chest 140(3), 768-774 (2011
32. Papi A, Romagnoli M, Baraldo S et al. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 162(5), 1773-1777 (2000
33. Hogg JC, Chu F, Utokaparch S et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 350(26), 2645-2653 (2004
34. Kirkham PA, Caramori G, Casolari P et al. Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 184(7), 796-802 (2011
35. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 64(8), 728-735 (2009
36. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. Eur. Respir. J. Suppl. 37, S1-S2 (2002
37. Gompertz S, Bayley DL, Hill SL, Stockley RA. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking-related COPD. Thorax 56(1), 36-41 (2001
38. Aaron SD, Angel JB, Lunau M et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 163(2), 349-355 (2001
39. Kinnula VL, Ilumets H, Myllarniemi M, Sovijarvi A, Rytila P. 8-isoprostane as a marker of oxidative stress in nonsymptomatic cigarette smokers and COPD. Eur. Respir. J. 29(1), 51-55 (2007
40. Montuschi P, Collins JV, Ciabattoni G et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care Med. 162(3 Pt 1), 1175-1177 (2000
41. Rahman I, van Schadewijk AA, Crowther AJ et al. 4-hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 166(4), 490-495 (2002
42. Rytila P, Rehn T, Ilumets H et al. Increased oxidative stress in asymptomatic current chronic smokers and GOLD stage 0 COPD. Respir. Res. 7, 69 (2006
43. Kinnula VL, Crapo JD. Superoxide dismutases in the lung and human lung diseases. Am. J. Respir. Crit. Care Med. 167(12), 1600-1619 (2003
44. Biswas SK, Rahman I. Environmental toxicity, redox signaling and lung inflammation: the role of glutathione. Mol. Aspects Med. 30(1-2), 60-76 (2009
45. Cantin AM, North SL, Hubbard RC, Crystal RG. Normal alveolar epithelial lining fluid contains high levels of glutathione. J. Appl. Physiol. 63(1), 152-157 (1987
46. Oury TD, Day BJ, Crapo JD. Extracellular superoxide dismutase: a regulator of nitric oxide bioavailability. Lab. Invest. 75(5), 617-636 (1996
47. Lakari E, Paakko P, Kinnula VL. Manganese superoxide dismutase, but not CuZn superoxide dismutase, is highly expressed in the granulomas of pulmonary sarcoidosis and extrinsic allergic alveolitis. Am. J. Respir. Crit. Care Med. 158(2), 589-596 (1998
48. Lakari E, Paakko P, Pietarinen-Runtti P, Kinnula VL. Manganese superoxide dismutase and catalase are coordinately expressed in the alveolar region in chronic interstitial pneumonias and granulomatous diseases of the lung. Am. J. Respir. Crit. Care Med. 161(2 Pt 1), 615-621 (2000
49. Oury TD, Chang LY, Marklund SL, Day BJ, Crapo JD. Immunocytochemical localization of extracellular superoxide dismutase in human lung. Lab. Invest. 70(6), 889-898 (1994
50. Wong GH, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 242(4880), 941-944 (1988
51. Gilks CB, Price K, Wright JL, Churg A. Antioxidant gene expression in rat lung after exposure to cigarette smoke. Am. J. Pathol. 152(1), 269-278 (1998
52. MacMillan-Crow LA, Crow JP, Thompson JA. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry 37(6), 1613-1622 (1998
53. Comhair SA, Xu W, Ghosh S et al. Superoxide dismutase inactivation in pathophysiology of asthmatic airway remodeling and reactivity. Am. J. Pathol. 166(3), 663-674 (2005
54. Li Y, Huang TT, Carlson EJ et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat. Genet. 11(4), 376-381 (1995
55. Foronjy RF, Mirochnitchenko O, Propokenko O et al. Superoxide dismutase expression attenuates cigarette smoke-or elastase-generated emphysema in mice. Am. J. Respir. Crit. Care Med. 173(6), 623-631 (2006
56. Brady TC, Chang LY, Day BJ, Crapo JD. Extracellular superoxide dismutase is upregulated with inducible nitric oxide synthase after NF-kB activation. Am. J. Physiol. 273(5 Pt 1), L1002-L1006 (1997
57. Carlsson LM, Jonsson J, Edlund T, Marklund SL. Mice lacking extracellular superoxide dismutase are more sensitive to hyperoxia. Proc. Natl Acad. Sci. USA 92(14), 6264-6268 (1995
58. Yao H, Arunachalam G, Hwang JW et al. Extracellular superoxide dismutase protects against pulmonary emphysema by attenuating oxidative fragmentation of ECM. Proc. Natl Acad. Sci. USA 107(35), 15571-15576 (2010
59. Gongora MC, Lob HE, Landmesser U et al. Loss of extracellular superoxide dismutase leads to acute lung damage in the presence of ambient air: a potential mechanism underlying adult respiratory distress syndrome. Am. J. Pathol. 173(4), 915-926 (2008
60. Folz RJ, Abushamaa AM, Suliman HB. Extracellular superoxide dismutase in the airways of transgenic mice reduces inflammation and attenuates lung toxicity following hyperoxia. J. Clin. Invest. 103(7), 1055-1066 (1999
61. Pietarinen P, Raivio K, Devlin RB, Crapo JD, Chang LY, Kinnula VL. Catalase and glutathione reductase protection of human alveolar macrophages during oxidant exposure in vitro. Am. J. Respir. Cell. Mol. Biol. 13(4), 434-441 (1995
62. Mossman BT, Marsh JP, Sesko A et al. Inhibition of lung injury, inflammation, and interstitial pulmonary fibrosis by polyethylene glycol-conjugated catalase in a rapid inhalation model of asbestosis. Am. Rev. Respir. Dis. 141(5 Pt 1), 1266-1271 (1990
63. Rahman I, Biswas SK, Jimenez LA, Torres M, Forman HJ. Glutathione, stress responses, and redox signaling in lung inflammation. Antioxid. Redox Signal 7(1-2), 42-59 (2005
64. Comhair SA, Bhathena PR, Farver C, Thunnissen FB, Erzurum SC. Extracellular glutathione peroxidase induction in asthmatic lungs: evidence for redox regulation of expression in human airway epithelial cells. FASEB J. 15(1), 70-78 (2001
65. Soini Y, Napankangas U, Jarvinen K, Kaarteenaho-Wiik R, Paakko P, Kinnula VL. Expression of g-glutamyl cysteine synthetase in non-small-cell lung carcinoma. Cancer 92(11), 2911-2919 (2001
66. Harju T, Mazur W, Merikallio H, Soini Y, Kinnula VL. Glutathione-S- transferases in lung and sputum specimens, effects of smoking and COPD severity. Respir. Res. 9, 80 (2008
67. Aesif SW, Anathy V, Havermans M et al. In situ analysis of protein S-glutathionylation in lung tissue using glutaredoxin-1-catalyzed cysteine derivatization. Am. J. Pathol. 175(1), 36-45 (2009
68. Aesif SW, Kuipers I, van der Velden J et al. Activation of the glutaredoxin-1 gene by nuclear factor-kB enhances signaling. Free Radic. Biol. Med. 51(6), 1249-1257 (2011
69. Peltoniemi M, Kaarteenaho-Wiik R, Saily M et al. Expression of glutaredoxin is highly cell specific in human lung and is decreased by transforming growth factor-b in vitro and in interstitial lung diseases in vivo. Hum. Pathol. 35(8), 1000-1007 (2004
70. Kuipers I, Guala AS, Aesif SW et al. Cigarette smoke targets glutaredoxin 1, increasing S-glutathionylation and epithelial cell death. Am. J. Respir. Cell. Mol. Biol. 45(5), 931-937 (2011
71. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47, 89-116 (2007
72. Rangasamy T, Guo J, Mitzner WA et al. Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J. Exp. Med. 202(1), 47-59 (2005
73. Sussan TE, Rangasamy T, Blake DJ et al. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice. Proc. Natl Acad. Sci. USA 106(1), 250-255 (2009
74. Giudice A, Arra C, Turco MC. Review of molecular mechanisms involved in the activation of the Nrf2-ARE signaling pathway by chemopreventive agents. Methods Mol. Biol. 647, 37-74 (2010
75. Singh A, Rangasamy T, Thimmulappa RK et al. Glutathione peroxidase 2, the major cigarette smoke-inducible isoform of GPX in lungs, is regulated by Nrf2. Am. J. Respir. Cell. Mol. Biol. 35(6), 639-650 (2006
76. Rangasamy T, Cho CY, Thimmulappa RK et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J. Clin. Invest. 114(9), 1248-1259 (2004
77. Iizuka T, Ishii Y, Itoh K et al. Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. Genes Cells 10(12), 1113-1125 (2005
78. Holmgren A. Antioxidant function of thioredoxin and glutaredoxin systems. Antioxid. Redox Signal 2(4), 811-820 (2000
79. Tiitto L, Kaarteenaho-Wiik R, Sormunen R et al. Expression of the thioredoxin system in interstitial lung disease. J. Pathol. 201(3), 363-370 (2003
80. Soini Y, Kahlos K, Napankangas U et al. Widespread expression of thioredoxin and thioredoxin reductase in non-small-cell lung carcinoma. Clin. Cancer Res. 7(6), 1750-1757 (2001
81. Li Y, Liu W, Xing G, Tian C, Zhu Y, He F. Direct association of hepatopoietin with thioredoxin constitutes a redox signal transduction in activation of AP-1/NF-kB. Cell Signal 17(8), 985-996 (2005
82. Sato A, Hoshino Y, Hara T et al. Thioredoxin-1 ameliorates cigarette smoke-induced lung inflammation and emphysema in mice. J. Pharmacol. Exp. Ther. 325(2), 380-388 (2008
83. Rhee SG, Kang SW, Netto LE, Seo MS, Stadtman ER. A family of novel peroxidases, peroxiredoxins. Biofactors 10(2-3), 207-209 (1999
84. Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem. Sci. 28(1), 32-40 (2003
85. Mo Y, Feinstein SI, Manevich Y et al. 1-Cys peroxiredoxin knock-out mice express mRNA but not protein for a highly related intronless gene. FEBS Lett. 555(2), 192-198 (2003)
86. Kinnula VL, Lehtonen S, Kaarteenaho-Wiik R et al. Cell-specific expression of peroxiredoxins in human lung and pulmonary sarcoidosis. Thorax 57(2), 157-164 (2002
87. Lehtonen ST, Svensk AM, Soini Y et al. Peroxiredoxins, a novel protein family in lung cancer. Int. J. Cancer 111(4), 514-521 (2004
88. Kinnula VL, Lehtonen S, Sormunen R et al. Overexpression of peroxiredoxins I, II, III, V and VI in malignant mesothelioma. J. Pathol. 196(3), 316-323 (2002
89. Neumann CA, Krause DS, Carman CV et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 424(6948), 561-565 (2003
90. Sundar IK, Chung S, Hwang JW et al. Peroxiredoxin-6 differentially regulates acute and chronic cigarette smoke-mediated lung inflammatory response and injury. Exp. Lung Res. 36(8), 451-462 (2010
91. Rhee SG, Woo HA. Multiple functions of peroxiredoxins: peroxidases, sensors and regulators of the intracellular messenger HO, and protein chaperones. Antioxid. Redox Signal 15(3), 781-794 (2011
92. Park JW, Mieyal JJ, Rhee SG, Chock PB. Deglutathionylation of 2-Cys peroxiredoxin is specifically catalyzed by sulfiredoxin. J. Biol. Chem. 284(35), 23364-23374 (2009
93. Chang TS, Jeong W, Woo HA, Lee SM, Park S, Rhee SG. Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. J. Biol. Chem. 279(49), 50994-51001 (2004
94. Baek JY, Han SH, Sung SH et al. Sulfiredoxin protein is critical for redox balance and survival of cells exposed to low steady-state levels of H2O2. J. Biol. Chem. 287(1), 81-89 (2012
95. Mazur W, Lindholm P, Vuorinen K, Myllarniemi M, Salmenkivi K, Kinnula VL. Cell-specific elevation of Nrf2 and sulfiredoxin-1 as markers of oxidative stress in the lungs of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. APMIS 118(9), 703-712 (2010
96. Singh A, Ling G, Suhasini AN et al. Nrf2-dependent sulfiredoxin-1 expression protects against cigarette smoke-induced oxidative stress in lungs. Free Radic. Biol. Med. 46(3), 376-386 (2009
97. Hackett NR, Heguy A, Harvey BG et al. Variability of antioxidant-related gene expression in the airway epithelium of cigarette smokers. Am. J. Respir. Cell. Mol. Biol. 29(3 Pt 1), 331-343 (2003
98. Pierrou S, Broberg P, O'Donnell RA et al. Expression of genes involved in oxidative stress responses in airway epithelial cells of smokers with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 175(6), 577-586 (2007
99. Harju T, Kaarteenaho-Wiik R, Sirvio R et al. Manganese superoxide dismutase is increased in the airways of smokers' lungs. Eur. Respir. J. 24(5), 765-771 (2004
100. Regan EA, Mazur W, Meoni E et al. Smoking and COPD increase sputum levels of extracellular superoxide dismutase. Free Radic. Biol. Med. 51(3), 726-732 (2011
101. Goven D, Boutten A, Lecon-Malas V et al. Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema. Thorax 63(10), 916-924 (2008
102. Malhotra D, Thimmulappa R, Navas-Acien A et al. Decline in Nrf2-regulated antioxidants in chronic obstructive pulmonary disease lungs due to loss of its positive regulator, DJ-1. Am. J. Respir. Crit. Care Med. 178(6), 592-604 (2008
103. Suzuki M, Betsuyaku T, Ito Y et al. Downregulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell. Mol. Biol. 39(6), 673-682 (2008
104. Blake DJ, Singh A, Kombairaju P et al. Deletion of Keap1 in the lung attenuates acute cigarette smoke-induced oxidative stress and inflammation. Am. J. Respir. Cell. Mol. Biol. 42(5), 524-536 (2010
105. Comhair SA, Erzurum SC. The regulation and role of extracellular glutathione peroxidase. Antioxid. Redox Signal 7(1-2), 72-79 (2005
106. Comhair SA, Lewis MJ, Bhathena PR et al. Increased glutathione and glutathione peroxidase in lungs of individuals with chronic beryllium disease. Am. J. Respir. Crit. Care Med. 159(6), 1824-1829 (1999
107. Golpon HA, Coldren CD, Zamora MR et al. Emphysema lung tissue gene expression profiling. Am. J. Respir. Cell Mol. Biol. 31(6), 595-600 (2004
108. Rahman I, van Schadewijk AA, Hiemstra PS et al. Localization of g-glutamylcysteine synthetase messenger RNA expression in lungs of smokers and patients with chronic obstructive pulmonary disease. Free Radic. Biol. Med. 28(6), 920-925 (2000
109. Harju T, Kaarteenaho-Wiik R, Soini Y, Sormunen R, Kinnula VL. Diminished immunoreactivity of g-glutamylcysteine synthetase in the airways of smokers' lung. Am. J. Respir. Crit. Care Med. 166(5), 754-759 (2002
110. Soini Y, Kaarteenaho-Wiik R, Paakko P, Kinnula V. Expression of antioxidant enzymes in bronchial metaplastic and dysplastic epithelium. Lung Cancer 39(1), 15-22 (2003
111. Harju TH, Peltoniemi MJ, Rytila PH et al. Glutathione S-transferase w in the lung and sputum supernatants of COPD patients. Respir. Res. 8, 48 (2007
112. Peltoniemi MJ, Rytila PH, Harju TH et al. Modulation of glutaredoxin in the lung and sputum of cigarette smokers and chronic obstructive pulmonary disease. Respir. Res. 7, 133 (2006
113. Maestrelli P, El Messlemani AH, De Fina O et al. Increased expression of heme oxygenase (HO)-1 in alveolar spaces and HO-2 in alveolar walls of smokers. Am. J. Respir. Crit. Care Med. 164(8 Pt 1), 1508-1513 (2001
114. Maestrelli P, Paska C, Saetta M et al. Decreased haem oxygenase-1 and increased inducible nitric oxide synthase in the lung of severe COPD patients. Eur. Respir. J. 21(6), 971-976 (2003
115. Lehtonen ST, Ohlmeier S, Kaarteenaho-Wiik R et al. Does the oxidative stress in chronic obstructive pulmonary disease cause thioredoxin/peroxiredoxin oxidation? Antioxid. Redox Signal. 10(4), 813-819 (2008
116. Lee EJ, In KH, Kim JH et al. Proteomic analysis in lung tissue of smokers and COPD patients. Chest 135(2), 344-352 (2009
117. Malhotra D, Thimmulappa RK, Mercado N et al. Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. J. Clin. Invest. 121(11), 4289-4302 (2011
118. Lawes CM, Thornley S, Young R et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim. Care Respir. J. 21(1), 35-40 (2012
119. Huang CC, Chan WL, Chen YC et al. Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan. Clin. Ther. 33(10), 1365-1370 (2011
120. Makita H, Nasuhara Y, Nagai K et al. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 62(11), 932-937 (2007
121. Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur. Respir. J. 16(2), 253-262 (2000
122. Decramer M, Dekhuijzen PN, Troosters T et al. The Bronchitis Randomized on NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS trial committee. Eur. Respir. J. 17(3), 329-336 (2001
123. Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365(9470), 1552-1560 (2005
124. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ 322(7297), 1271-1274 (2001
125. Poole PJ, Black PN. Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents. Am. J. Respir. Med. 2(5), 367-370 (2003
126. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin. Ther. 22(2), 209-221 (2000
127. Black PN, Morgan-Day A, McMillan TE, Poole PJ, Young RP. Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease [ISRCTN21676344]. BMC Pulm. Med. 4, 13 (2004
128. Moretti M, Bottrighi P, Dallari R et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE study. Drugs Exp. Clin. Res. 30(4), 143-152 (2004
129. Zheng JP, Kang J, Huang SG et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study. Lancet 371(9629), 2013-2018 (2008
130. Gillissen A, Jaworska M, Orth M et al. Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Respir. Med. 91(3), 159-168 (1997
131. Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 1(3), 307-316 (2007
132. Moretti M. Erdosteine: its relevance in COPD treatment. Expert Opin. Drug Metab. Toxicol. 5(3), 333-343 (2009
133. Cazzola M, Floriani I, Page CP. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. Pulm. Pharmacol. Ther. 23(2), 135-144 (2010
134. Braga PC, Allegra L, Rampoldi C, Ornaghi A, Beghi G. Long-lasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteine-lysine to patients with chronic bronchitis. Respiration 57(6), 353-358 (1990
135. Cakan G, Turkoz M, Turan T, Ahmed K, Nagatake T. S-carboxymethylcysteine inhibits the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells. Microb. Pathog. 34(6), 261-265 (2003
136. Tatsumi K, Fukuchi Y. Carbocisteine improves quality of life in patients with chronic obstructive pulmonary disease. J. Am. Geriatr. Soc. 55(11), 1884-1886 (2007
137. Aylward M. An assessment of S-carboxymethylcysteine in the treatment of chronic bronchitis. Curr. Med. Res. Opin. 2(7), 387-394 (1974
138. Edwards GF, Steel AE, Scott JK, Jordan JW. S-carboxymethylcysteine in the fluidification of sputum and treatment of chronic airway obstruction. Chest 70(4), 506-513 (1976
139. Miskoviti G, Szule P, Mescaros K. Double-blind study of carbocysteine against placebo in chronic bronchitis; mucoregulation in respiratory tract disorders. Proc. R. Soc. Med. 5, 1-3 (1982
140. Allegra L, Cordaro CI, Grassi C. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. Respiration 63(3), 174-180 (1996
141. Grillage M, Barnard-Jones K. Long-term oral carbocisteine therapy in patients with chronic bronchitis. A double blind trial with placebo control. Br. J. Clin. Pract. 39(10), 395-398 (1985
142. Yasuda H, Yamaya M, Sasaki T et al. Carbocisteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J. Am. Geriatr. Soc. 54(2), 378-380 (2006
143. Yasuda H, Yamaya M, Sasaki T et al. Carbocisteine inhibits rhinovirus infection in human tracheal epithelial cells. Eur. Respir. J. 28(1), 51-58 (2006
144. Rhee CK, Kang CM, You MB et al. Effect of fudosteine on mucin production. Eur. Respir. J. 32(5), 1195-1202 (2008
145. Komatsu H, Yamaguchi S, Komorita N et al. Inhibition of endotoxin-and antigen-induced airway inflammation by fudosteine, a mucoactive agent. Pulm. Pharmacol. Ther. 18(2), 121-127 (2005
146. Nagaoka S, Takishima T, Nagano H et al. Phase III clinical study of SS320A. Double-blind trial in comparison with placebo. J. Clin. Ther. Med. 18(1), 109-140 (2002
147. Ekberg-Jansson A, Larson M, MacNee W et al. N-isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. Eur. Respir. J. 13(4), 829-834 (1999
148. Moncaster JA, Walsh DT, Gentleman SM, Jen LS, Aruoma OI. Ergothioneine treatment protects neurons against N-methyl-d-aspartate excitotoxicity in anin vivo rat retinal model. Neurosci. Lett. 328(1), 55-59 (2002
149. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 62(18), 5196-5203 (2002
150. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, Kensler TW. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J. Biol. Chem. 278(10), 8135-8145 (2003
151. Balogun E, Hoque M, Gong P et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem. J. 371(Pt 3), 887-895 (2003
152. Go ML, Wu X, Liu XL. Chalcones: an update on cytotoxic and chemoprotective properties. Curr. Med. Chem. 12(4), 481-499 (2005
153. Wei BL, Teng CH, Wang JP, Won SJ, Lin CN. Synthetic 2́,5́- dimethoxychalcones as G(2)/M arrest-mediated apoptosis-inducing agents and inhibitors of nitric oxide production in rat macrophages. Eur. J. Med. Chem. 42(5), 660-668 (2007
154. Lee JH, Jung HS, Giang PM et al. Blockade of nuclear factor-kB signaling pathway and anti-inflammatory activity of cardamomin, a chalcone analog from Alpinia conchigera. J. Pharmacol. Exp. Ther. 316(1), 271-278 (2006
155. Kumar V, Kumar S, Hassan M et al. Novel chalcone derivatives as potent Nrf2 activators in mice and human lung epithelial cells. J. Med. Chem. 54(12), 4147-4159 (2011
156. Tajima S, Bando M, Ishii Y et al. Effects of edaravone, a free-radical scavenger, on bleomycin-induced lung injury in mice. Eur. Respir. J. 32(5), 1337-1343 (2008
157. Kikuchi K, Uchikado H, Miyagi N et al. Beyond neurological disease: new targets for edaravone (review). Int. J. Mol. Med. 28(6), 899-906 (2011
158. Aldini G, Vistoli G, Regazzoni L, Benfatto MC, Bettinelli I, Carini M. Edaravone inhibits protein carbonylation by a direct carbonyl-scavenging mechanism: focus on reactivity, selectivity, and reaction mechanisms. Antioxid. Redox Signal. 12(3), 381-392 (2010
159. Ito K, Ozasa H, Horikawa S. Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat. Free Radic. Biol. Med. 38(3), 369-374 (2005
160. Aldini G, Dalle-Donne I, Facino RM, Milzani A, Carini M. Intervention strategies to inhibit protein carbonylation by lipoxidation-derived reactive carbonyls. Med. Res. Rev. 27(6), 817-868 (2007
161. Aldini G, Dalle-Donne I, Colombo R, Maffei Facino R, Milzani A, Carini M. Lipoxidation-derived reactive carbonyl species as potential drug targets in preventing protein carbonylation and related cellular dysfunction. Chem. Med. Chem. 1(10), 1045-1058 (2006
162. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 321(5895), 1493-1495 (2008
163. Braughler JM, Pregenzer JF, Chase RL, Duncan LA, Jacobsen EJ, McCall JM. Novel 21-amino steroids as potent inhibitors of iron-dependent lipid peroxidation. J. Biol. Chem. 262(22), 10438-10440 (1987
164. Miniati M, Cocci F, Monti S et al. Lazaroid U-74389F attenuates phorbol ester-induced lung injury in rabbits. Eur. Respir. J. 9(4), 758-764 (1996
165. Tuder RM, Zhen L, Cho CY et al. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am. J. Respir. Cell. Mol. Biol. 29(1), 88-97 (2003
166. Muscoli C, Sacco I, Alecce W et al. The protective effect of superoxide dismutase mimetic M40401 on balloon injury-related neointima formation: role of the lectin-like oxidized low-density lipoprotein receptor-1. J. Pharmacol. Exp. Ther. 311(1), 44-50 (2004
167. Chang LY, Crapo JD. Inhibition of airway inflammation and hyper-reactivity by an antioxidant mimetic. Free Radic. Biol. Med. 33(3), 379-386 (2002
168. Smith KR, Uyeminami DL, Kodavanti UP, Crapo JD, Chang LY, Pinkerton KE. Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant. Free Radic. Biol. Med. 33(8), 1106-1114 (2002
169. Sharpe MA, Ollosson R, Stewart VC, Clark JB. Oxidation of nitric oxide by oxomanganese-salen complexes: a new mechanism for cellular protection by superoxide dismutase/catalase mimetics. Biochem. J. 366(Pt 1), 97-107 (2002
170. Day BJ, Shawen S, Liochev SI, Crapo JD. A metalloporphyrin superoxide dismutase mimetic protects against paraquat-induced endothelial cell injury in vitro. J. Pharmacol. Exp. Ther. 275(3), 1227-1232 (1995
171. Day BJ, Fridovich I, Crapo JD. Manganic porphyrins possess catalase activity and protect endothelial cells against hydrogen peroxide-mediated injury. Arch. Biochem. Biophys. 347(2), 256-262 (1997
172. Ferrer-Sueta G, Vitturi D, Batinic-Haberle I et al. Reactions of manganese porphyrins with peroxynitrite and carbonate radical anion. J. Biol. Chem. 278(30), 27432-27438 (2003
173. Tse HM, Milton MJ, Piganelli JD. Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: implication for their use in targeting oxidation-reduction reactions in innate immunity. Free Radic. Biol. Med. 36(2), 233-247 (2004
174. Vujaskovic Z, Batinic-Haberle I, Rabbani ZN et al. A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic. Biol. Med. 33(6), 857-863 (2002
175. Piganelli JD, Flores SC, Cruz C et al. A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. Diabetes 51(2), 347-355 (2002
176. Zhang HJ, Doctrow SR, Xu L et al. Redox modulation of the liver with chronic antioxidant enzyme mimetic treatment prevents age-related oxidative damage associated with environmental stress. FASEB J. 18(13), 1547-1549 (2004
177. Zhang HJ, Doctrow SR, Oberley LW, Kregel KC. Chronic antioxidant enzyme mimetic treatment differentially modulates hyperthermia-induced liver HSP70 expression with aging. J. Appl. Physiol. 100(4), 1385-1391 (2006
178. Souza DG, Vieira AT, Pinho V et al. NF-kB plays a major role during the systemic and local acute inflammatory response followingintestinal reperfusion injury. Br. J. Pharmacol. 145(2), 246-254 (2005
179. Nguyen C, Teo JL, Matsuda A et al. Chemogenomic identification of Ref-1/ AP-1 as a therapeutic target for asthma. Proc. Natl Acad. Sci. USA 100(3), 1169-1173 (2003
180. Bachnoff N, Trus M, Atlas D. Alleviation of oxidative stress by potent and selective thioredoxin-mimetic peptides. Free Radic. Biol. Med. 50(10), 1355-1367 (2011
181. Stefanutti G, Pierro A, Smith VV, Klein NJ, Eaton S. Peroxynitrite decomposition catalyst FeTMPyP provides partial protection against intestinal ischemia and reperfusion injury in infant rats. Pediatr. Res. 62(1), 43-48 (2007
182. Pacher P, Liaudet L, Bai P et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 107(6), 896-904 (2003
183. Cuzzocrea S, Thiemermann C, Salvemini D. Potential therapeutic effect of antioxidant therapy in shock and inflammation. Curr. Med. Chem. 11(9), 1147-1162 (2004
184. Shi H, Timmins G, Monske M et al. Evaluation of spin trapping agents and trapping conditions for detection of cell-generated reactive oxygen species. Arch. Biochem. Biophys. 437(1), 59-68 (2005
185. Osoata GO, Yamamura S, Ito M et al. Nitration of distinct tyrosine residues causes inactivation of histone deacetylase-2. Biochem. Biophys. Res. Commun. 384(3), 366-371 (2009
186. Nott A, Watson PM, Robinson JD, Crepaldi L, Riccio A. S-nitrosylation of histone deacetylase-2 induces chromatin remodelling in neurons. Nature 455(7211), 411-415 (2008
187. Valenca SS, Rueff-Barroso CR, Pimenta WA et al. l-NAME and l-arginine differentially ameliorate cigarette smoke-induced emphysema in mice. Pulm. Pharmacol. Ther. 24(5), 587-594 (2011
188. Seimetz M, Parajuli N, Pichl A et al. Inducible NOS inhibition reverses tobacco smoke-induced emphysema and pulmonary hypertension in mice. Cell 147(2), 293-305 (2011
189. Kinnula VL, Crapo JD. Superoxide dismutases in malignant cells and human tumors. Free Radic. Biol. Med. 36(6), 718-744 (2004
190. Kinnula VL, Paakko P, Soini Y. Antioxidant enzymes and redox regulating thiol proteins in malignancies of human lung. FEBS Lett. 569(1-3), 1-6 (2004)